Angela Lamarca
Oncologist who was lead author of ABC-06, the first randomised trial to show that second-line chemotherapy helps people with advanced bile duct cancer.
Overview
Angela Lamarca trained and worked at The Christie in Manchester before moving to Madrid. She was first author of the 2021 Lancet Oncology report of ABC-06, the UK trial that showed FOLFOX plus active symptom control lengthened survival compared with symptom control alone after gemcitabine and cisplatin in advanced biliary tract cancer, establishing a second-line standard. She also works on neuroendocrine tumours.
Similar pages
not linked directly; found by shared links- PersonJuan W. Valle
Shares ABC-06, Biliary tract cancer (cholangiocarcinoma) and the tags biliary, trialist.
- PersonJohn N. Primrose
Shares Biliary tract cancer (all types) and the tags biliary, trialist.
- PersonRobin Kate Kelley
Shares Biliary tract cancer (all types) and the tags biliary, trialist.
- PersonGhassan K. Abou-Alfa
Shares Biliary tract cancer (cholangiocarcinoma) and the tags biliary, trialist.
- PersonAndrew X. Zhu
Shares the tags biliary, trialist.
- PersonJames C. Yao
Shares Neuroendocrine tumours and the tag trialist.
- PersonLipika Goyal
Shares Biliary tract cancer (cholangiocarcinoma) and the tag biliary.
- PersonJennifer A. Chan
Shares Neuroendocrine tumours and the tag trialist.